N/A N=60 Urinary Cytokines in Patients With Overactive Bladder (OAB)
Overactive Bladder · Urinary Tract Infection
Primary: Number of Participants With Elevated Cytokines (Levels of Pro-inflammatory) — 20; 20; 16 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=18 Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?
Overactive Bladder
Primary: Number of Subjects With Evidence of Bacteria in Urine Sample by Microbiologic Evaluation — 8; 1 participants
Phase 3 N=143 Behavioral Treatment of Overactive Bladder in Men
Overactive Bladder
Primary: 24-hour Voiding Frequency — 9.1; 9.5 voids per 24-hour day — p=.001
N/A N=20 Hypnotherapy for Treatment of Overactive Bladder
Overactive Bladder
Primary: Change in Overactive Bladder Symptoms (Based on OABqSF) — -19; -33.4 units on a scale — p=.07
Phase 2 N=550 SMP-986 Phase 2 Proof of Concept in Patients With Overactive Bladder Syndrome (OABS)
Overactive Bladder Syndrome (OABS)
Primary: Change From Baseline to Week 8 in the Number of Voids/24 Hours — -1.06; -1.44; -1.78; -2.41 voids/24 hrs.
Phase 4 N=100 Overactive Bladder Innovative Therapy Trial (OrBIT)
Overactive Bladder
Primary: Frequency of Voids at 12 Weeks — -2.4; -2.5 Voids/day
N/A N=96 FREEOAB Study for Overactive Bladder
Overactive Bladder · Urinary Frequency · Urinary Incontinence, Urge
Primary: Percentage of Responders in Voiding (Urinary Frequency) Events — 55 Participants
Phase 4 N=84 Mirabegron and Urinary Urgency Incontinence
Overactive Bladder
Primary: Response to Therapy — 15; 29 Participants
Phase 4 N=254 OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
Overactive Bladder
Primary: Percentage of Participants Who Achieve a 100% Reduction in Urinary Incontinence Episodes — 32.0; 7.2 percentage of participants
Phase 3 N=356 A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence
Overactive Bladder · Urinary Incontinence
Primary: Change From Study Baseline in Number of Episodes of Urinary Incontinence in Treatment Cycle 1 — 4.86; 5.23; 4.38; -3.10 Incontinence Episodes
Phase 4 N=70 The Efficacy of Solifenacin With or Without Tamsulosin in Adult Women With Overactive Bladder (OAB)
Overactive Bladder
Primary: Change in Mean Number of Micturition Episodes Per 24 Hours — -1.9; -2.2 episodes
N/A N=20 A Trial of Transcutaneous Nerve Stimulation for OAB
Overactive Bladder
Primary: Patient Reported Outcome Measure (Patient Percention of Bladder Condition Question) — 4; 3 units on a scale
Phase 3 N=249 Anticholinergic vs. Botox Comparison Study
Urge Urinary Incontinence · Overactive Bladder
Primary: Change in Urge Urinary Incontinence (UUI) Episodes — -3.13; -3.15; -3.32; -3.25 Mean change in UUI episodes from baselin
N/A N=21 Comparative Urine Proteomic Studies of Overactive Bladder in Humans
Overactive Bladder
Primary: Bladder Diary to Assess Urinary Frequency at Baseline and at End of 6-week Treatment — 12.32; 10.79 urinations/day — p=0.19
Phase 2 N=134 Bacterial Genomic Sequencing in Overactive Bladder
Overactive Bladder
Primary: Bacterial Genomic Sequencing — 25; 11; 3; 6 participants
Phase 2 N=80 URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
Overactive Bladder With Urge Urinary Incontinence
Primary: Change From Baseline at Week 12 in Average Daily Number of Urgency Episodes — -1.13; -2.43; -3.37 Urgency episodes per day — p==0.1722
Phase 4 N=74 Fall Prevention in Older Adults With OAB
Overactive Bladder
Primary: Measure of Physical Activity — 1634.19 steps per day
Phase 3 N=248 Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder
Urinary Bladder, Overactive
Primary: Treatment Phase 1 (Treatment Cycle 1): Change From Baseline in the Daily Average Number of Urinary Incontinence Episodes at Week 12 After the First Treatment — -1.25…
Phase 4 N=127 Trospium Chloride XR in Obese Female Patients With Overactive Bladder
Obesity · Overactive Bladder · Incontinence
Primary: Percent Change From Baseline in Urinary Urgency Incontinence (UUI) — -23.7; 57.8 Percent change
N/A N=74 Clinical Trial to Study a Non-invasive Neurostimulation Device on Urgency (Urinary) Incontinence Overactive Bladder (OAB)
Overactive Bladder
Primary: Change in Mean Daily Urgency Incontinence Episodes — -2.5; -2.5 number of incontinence episodes/24 hours
Phase 4 N=147 InSite for Over Active Bladder
Urinary Incontinence, Urgency-frequency · Overactive Bladder
Primary: Randomized Cohort: OAB Therapeutic Response — 61; 42 percentage of participants with response — p=0.016
Phase 4 N=345 An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants
Urinary Bladder, Overactive
Primary: Percentage of Participants Who Achieved Treatment Goal — 40.45 Percentage of participants
Phase 4 N=132 Evaluating the Change of Overactive Bladder Symptoms in Women Post Pubovaginal Sling Procedure for Stress Incontinence
Urinary Bladder, Overactive
Primary: Change in OAB Symptoms Post Pubovaginal Sling Operation — 63; 21; 4 participants — p=0.001
Phase 2 N=156 Safety and Efficacy Study of AGN-214868 in Patients With Idiopathic Overactive Bladder and Urinary Incontinence
Urinary Bladder, Overactive
Primary: Change From Baseline in the Daily Average Number of Micturition (Urination) Episodes — 13.7; 12.2; 11.0; 10.6 Episodes
Phase 4 N=768 Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life
Urinary Bladder, Overactive
Primary: Change From Baseline to End of Treatment in Overactive Bladder Questionnairre (OAB-q) Symptom Bother Score — 57.9; 58.2; 37.5; 28.3 OAB-q Score — p=<0.0001
N/A N=150 The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
Overactive Bladder · Urinary Incontinence · Urinary Frequency or Urgency Adverse Event
Primary: Day Urinary Frequency — 7.68; 10.95 number of diurnal micturitions per day
Phase 2 N=62 Effects and Safety of Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome
Overactive Bladder
Primary: Mean Change of the Total Frequency Per 3 Days — -4.64; -0.19 Frequency per 3 days
Phase 3 N=1,105 Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
Overactive Bladder
Primary: Change From Baseline at Week 12 in the Average Number of Micturition Episodes Per Day — -2.04; -1.30 Micturitions per day — p=<0.0001
Phase 3 N=883 Fesoterodine Flexible Dose Study
Overactive Bladder
Primary: Change in Mean Number of Micturition Episodes Per 24 Hours at Week 12 Relative to Baseline. — -2.1; -2.9 number of episodes per 24 hours — p=0.0002
Phase 3 N=548 Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
Overactive Bladder
Primary: Change From Baseline in Number of Daily Episodes of Urinary Incontinence — 5.52; 5.70; -2.95; -1.03 Incontinence episodes